Primary Open Angle Glaucoma study: REGN22530
Official title REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
ClinicalTrials.gov ID: NCT07675824
What this study is testing
What is REGN22530?
This is an investigational drug being studied to see if it can help treat primary open angle glaucoma or ocular hypertension. It is designed to attach to a specific protein in the eye to stop it from working, which may help fluid drain out and lower pressure.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn about side effects, how much drug reaches the eye, immune reactions, and how eye pressure changes after taking REGN22530, to understand its effectiveness.
- Who it's for
- Adults who have primary open angle glaucoma or ocular hypertension.
- What's involved
- Participants will receive the study drug and attend clinic visits where eye pressure and other tests are performed.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol
- Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to...
- BCVA of ≥55 EDTRS letters (Snellen equivalent of better than or equal to 20/80) in the non-study eye on day 1
- Phakic or pseudophakic with a posterior chamber intraocular lens that has been implanted ≥3 months prior to Screening Visit 1
- Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality posterior segment imaging in the study eye Key
You likely can't join if
- Ocular-specific exclusion criteria apply to the Study Eye only, unless otherwise specified.
- OAG or OHT secondary to pigment dispersion, pseudoexfoliation, trauma, uveitis, neovascularization, a vascular disorder, or steroid use
- Congenital or traumatic cataract, or visually significant cataract that is likely to require surgical intervention during the study
- Presence of significant corneal scarring or irregularities that could interfere with reliable IOP measurement
- Prior incisional or bleb-forming glaucoma surgery, suprachoroidal procedures, Trabecular Meshwork (TM)-stripping Microinvasive Glaucoma Surgery...
- History of Selective Laser Trabeculoplasty (SLT) within 6 months prior to day 1
See the full eligibility criteria
- Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol
- Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to 20/200) in the study eye on day 1
- BCVA of ≥55 EDTRS letters (Snellen equivalent of better than or equal to 20/80) in the non-study eye on day 1
- Phakic or pseudophakic with a posterior chamber intraocular lens that has been implanted ≥3 months prior to Screening Visit 1
- Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality posterior segment imaging in the study eye Key
- Ocular-specific exclusion criteria apply to the Study Eye only, unless otherwise specified.
- OAG or OHT secondary to pigment dispersion, pseudoexfoliation, trauma, uveitis, neovascularization, a vascular disorder, or steroid use
- Congenital or traumatic cataract, or visually significant cataract that is likely to require surgical intervention during the study
- Presence of significant corneal scarring or irregularities that could interfere with reliable IOP measurement
- Prior incisional or bleb-forming glaucoma surgery, suprachoroidal procedures, Trabecular Meshwork (TM)-stripping Microinvasive Glaucoma Surgery (MIGS), angle-based implants other than iStent or iridectomy/iridotomy as...
- History of Selective Laser Trabeculoplasty (SLT) within 6 months prior to day 1
- History of transscleral (including micropulse) or endoscopic cyclophotocoagulation within 1 year prior to day 1 Note: Other protocol defined Inclusion/ Exclusion criteria apply
The study team makes the final eligibility decision.
Where it is enrolling
- Deerfield Beach, Florida, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Deerfield Beach, Florida, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.